• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

    2/11/22 12:15:01 PM ET
    $EVGN
    Agricultural Chemicals
    Industrials
    Get the next $EVGN alert in real time by email
    SC 13G/A 1 d294204dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 9)*

     

     

    Evogene Ltd.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    M4119S104

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. M4199S104

     

    1.    Names of Reporting Persons

     

    Macquarie Group Limited

    2.    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☒        (b)  ☐

    3.    SEC Use Only

     

    4.        Citizenship or Place of Organization

     

    Sydney, New South Wales Australia

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

       5.       

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    0

    9.        Aggregate Amount Beneficially Owned by Each Reporting Person

     

    183,210 deemed beneficially owned due to reporting person’s ownership of Macquarie Bank Limited whose individual holdings are shown on the following forms.

    10.    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.    Percent of Class Represented by Amount in Row (9)

     

    0.43%

    12.    Type of Reporting Person (See Instructions)

     

    HC

     

    Page 2 of 10


    CUSIP No. M4199S104

     

    1.    Names of Reporting Persons

     

    Macquarie Bank Limited

    2.    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ☒        (b)  ☐

    3.    SEC Use Only

     

    4.        Citizenship or Place of Organization

     

    Sydney, New South Wales, Australia

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

       5.       

    Sole Voting Power

     

    0

       6.   

    Shared Voting Power

     

    0

       7.   

    Sole Dispositive Power

     

    0

       8.   

    Shared Dispositive Power

     

    0

    9.        Aggregate Amount Beneficially Owned by Each Reporting Person

     

    183,210

    10.    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ☐

    11.    Percent of Class Represented by Amount in Row (9)

     

    0.43%

    12.    Type of Reporting Person (See Instructions)

     

    CO

     

    Page 3 of 10


    Item 1.

       (a)   

    Name of Issuer
    Evogene Ltd

       (b)   

    Address of Issuer’s Principal Executive Offices
    13 Gad Feinstein St., Park Rehovot, Rehovot, Israel

    Item 2.
       (a)   

    Name of Person Filing
    This Schedule 13G is jointly filed by Macquarie Group Limited, Macquarie Bank Limited

       (b)   

    Address of Principal Business Office or, if none, Residence
    The principal business address of Macquarie Group Limited Macquarie Bank Limited is 50 Martin Place Sydney, New South Wales, Australia.

       (c)   

    Citizenship
    Macquarie Group Limited, Macquarie Bank Limited - Sydney, New South Wales, Australia Corporation

       (d)   

    Title of Class of Securities
    Common Stock

       (e)   

    CUSIP Number
    M4199S104

    Item 3.    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
       (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
       (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
       (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
       (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
       (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                                                     

     

    Page 4 of 10


    Item 4.    Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

       (a)   

    Amount beneficially owned:

    See responses on the cover page hereto.

       (b)   

    Percent of class:

    See responses on the cover page hereto.

       (c)   

    Number of shares as to which the person has:

     

              (i)   

    Sole power to vote or to direct the vote

    See responses on the cover page hereto.

              (ii)   

    Shared power to vote or to direct the vote

    0

              (iii)   

    Sole power to dispose or to direct the disposition of

    See responses on the cover page hereto.

              (iv)   

    Shared power to dispose or to direct the disposition of

    0

     

    Item 5.    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ☒

     

    Item 6.    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

    See Exhibit A.

     

    Item 8.    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.    Notice of Dissolution of Group

    Not applicable.

     

    Page 5 of 10


    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Group Limited   

    February 11, 2022

       Date
    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

    Macquarie Bank Limited   

    February 11, 2022

       Date
    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Macquarie Management Holdings, Inc.

      

    February 11, 2022

       Date

    /s/ Brian L. Murray

      
    Signature   

     

      

    Brian L. Murray

    Chief Compliance Officer

      
    Macquarie Investment Management Business Trust   

    February 11, 2022

       Date

    /s/ Brian L. Murray

      
    Signature   

     

      

    Brian L. Murray

    Chief Compliance Officer

      

     

    Page 6 of 10


    EXHIBIT A

    AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS

    AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”).

    WHEREAS, the parties hereto may be deemed to be the direct or indirect beneficial owners of the same equity securities for the purpose of the reporting requirements of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and

    WHEREAS, the regulations promulgated under Section 13(d) of the Exchange Act permit the joining of such beneficial owners in the filing of a single Joint Acquisition Statement reporting such ownership to the Securities and Exchange Commission.

    NOW, THEREFORE, in consideration of the mutual covenants herein contained, and each of the parties hereto intending to be legally bound, it is agreed as follows:

    1.    In the event that any two or more parties shall be deemed to be the direct or indirect beneficial owners of the same equity security required to be reported to the Securities and Exchange Commission such parties may join together in the filing of a Joint Acquisition Statement with respect to that security. Additional persons who may after the date hereof be deemed to be the direct or indirect beneficial owners of the same equity security as a party hereto and required to be reported to the Securities and Exchange Commission (a “New Party”) may be added as a party this agreement by signing a counterpart hereof. An amendment to this agreement is deemed effective upon the signature of such new party and the amendment of the applicable Annex which may be affixed to this agreement as amended. Each party hereto agrees that this agreement, as it may be amended from time to time as provided herein, is a valid and binding agreement of each such party.

    2.    With respect to each Joint Acquisition Statement in which a party joins, each party acknowledges that (a) it will be eligible under applicable regulations of the Securities and Exchange Commission to join in the filing and (b) it will be responsible for the timely filing of such statement and any amendments thereto and the completeness and accuracy of the information concerning such party; but each such party shall not be responsible for the completeness and accuracy of the information concerning the other parties making the filing, unless such party knows or has reason to believe that such information with respect to such other parties is inaccurate.

    3.    The parties consent to the inclusion of a copy of this agreement as an exhibit to any Joint Acquisition Statement filed on behalf of any of them.

     

    Page 7 of 10


    IN WITNESS WHEREOF, the parties hereto have executed this agreement by their duly authorized officers as of the date set forth above.

    DELAWARE FUNDS® BY MACQUARIE (listed on Annex A hereto)

    ATTEST BY:

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    MACQUARIE MANAGEMENT HOLDINGS, INC.

     

    /s/ Brian L. Murray    /s/ David Connor
    Signature    Signature
                            

    Brian L. Murray

    Chief Compliance Officer

      

    David Connor

    General Counsel

    THE MACQUARIE PARTIES (LISTED ON ANNEX B HERETO)

    ATTEST BY:

     

    /s/ Paul Peduto    /s/ Charles Glorioso
    Signature    Signature
                            

    Paul Peduto

    Associate Director

      

    Charles Glorioso

    Division Director

     

    Page 8 of 10


    Annex A— Delaware FundsSM by Macquarie

    DELAWARE GROUP EQUITY FUNDS I

    DELAWARE GROUP EQUITY FUNDS II

    DELAWARE GROUP EQUITY FUNDS IV

    DELAWARE GROUP EQUITY FUNDS V

    DELAWARE GROUP INCOME FUNDS

    DELAWARE GROUP LIMITED-TERM GOVERNMENT FUNDS

    DELAWARE GROUP CASH RESERVE

    DELAWARE GROUP GOVERNMENT FUND

    DELAWARE GROUP STATE TAX-FREE INCOME TRUST

    DELAWARE GROUP TAX-FREE FUND

    DELAWARE GROUP GLOBAL & INTERNATIONAL FUNDS

    DELAWARE GROUP ADVISER FUNDS

    DELAWARE VIP TRUST

    DELAWARE POOLED TRUST

    DELAWARE GROUP FOUNDATION FUNDS

    DELAWARE INVESTMENTS DIVIDEND AND INCOME FUND, INC.

    DELAWARE ENHANCED GLOBAL DIVIDEND AND INCOME FUND

    INVESTED PORTFOLIOS

    IVY HIGH INCOME OPPORTUNITIES FUND

    IVY FUNDS

    IVY VARIABLE INSURANCE PORTFOLIOSSM

    VOYAGEUR INSURED FUNDS

    VOYAGEUR INTERMEDIATE TAX FREE FUNDS

    VOYAGEUR MUTUAL FUNDS

    VOYAGEUR MUTUAL FUNDS II

    VOYAGEUR MUTUAL FUNDS III

    VOYAGEUR TAX FREE FUNDS

    DELAWARE INVESTMENTS COLORADO MUNICIPAL INCOME FUND, INC.

    DELAWARE INVESTMENTS NATIONAL MUNICIPAL INCOME FUND

    DELAWARE INVESTMENTS MINNESOTA MUNICIPAL INCOME FUND II, INC.

     

    Page 9 of 10


    Annex B — the Macquarie Parties

    Macquarie Group Limited

    Macquarie Bank Limited

    Macquarie Affiliated Managers (USA) Inc.

    Macquarie Affiliated Managers Holdings (USA) Inc.

    Macquarie Americas Holdings Pty Ltd.

    Macquarie B.H. Pty Limited

    Macquarie FG Holdings Inc.

    Macquarie Funding Holdings LLC

    Macquarie Investment Management Europe Limited

    EXHIBIT B

    Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021.

     

    Page 10 of 10

    Get the next $EVGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVGN

    DatePrice TargetRatingAnalyst
    11/24/2021$8.00 → $7.00Outperform
    RBC Capital
    10/8/2021$7.00Buy
    ROTH Capital
    8/23/2021$8.00Outperform
    RBC Capital
    7/29/2021$10.00Buy
    Aegis Capital
    More analyst ratings

    $EVGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

      Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.     The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions. Lavie

      4/21/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    SEC Filings

    See more
    • SEC Form 6-K filed by Evogene Ltd

      6-K - Evogene Ltd. (0001574565) (Filer)

      4/21/25 7:00:10 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form EFFECT filed by Evogene Ltd

      EFFECT - Evogene Ltd. (0001574565) (Filer)

      4/3/25 12:15:13 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form POS AM filed by Evogene Ltd

      POS AM - Evogene Ltd. (0001574565) (Filer)

      3/28/25 6:09:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Financials

    Live finance-specific insights

    See more
    • Evogene Schedules First Quarter 2025 Financial Results Release

      Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel, May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://www.veidan-conferenceing.com/evogene The entire conference will be available online on the company's website a fe

      5/8/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

      Conference call and webcast: today, March 6, 2025, 9:00 am ET Financial Highlights: In the year 2024, total revenues reached approximately $8.5 million compared to approximately $5.6 million in the year 2023. The increase in revenues is mainly due to increase in AgPlenus' revenues from its collaboration with Bayer and an increase in Casterra's seed sales.In Q4 2024, total revenues reached approximately $1.6 million compared to approximately $0.6 million in Q4 2023. The increase in revenues is mainly due to the increase in Casterra's seed sales.Revenues in Q4 2024 were originally expected to be higher, however, there was a change in delivery schedule of Casterra's seeds from 2024 to 2025. In

      3/6/25 7:15:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Evogene Schedules Fourth Quarter 2024 Financial Results Release

      Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel, Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's

      2/20/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evogene Ltd

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      10/15/24 6:52:26 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G filed by Evogene Ltd

      SC 13G - Evogene Ltd. (0001574565) (Subject)

      2/14/24 8:30:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Evogene Ltd (Amendment)

      SC 13G/A - Evogene Ltd. (0001574565) (Subject)

      2/11/22 12:15:01 PM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

      Mr. Nir Nirmodi is Replacing Ms. Sarit Firon, who will Continue Serving as a Member of the Board REHOVOT, Israel, March 6, 2025 /PRNewswire/ -- Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board. As Evogene progresses toward key milestones across its subsidiaries and programs, Mr. Nimrodi's extensive experience in scaling life sciences businesses and driving growth make

      3/6/25 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

      Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel, Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (NASDAQ:EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. Casterra entered a new phase in its l

      12/19/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • AgPlenus Appoints Dr. Adrian Percy to Its Board of Directors

      REHOVOT, Israel, July 12, 2023 /PRNewswire/ -- AgPlenus Ltd., an innovative company designing novel and safe crop protection products allowing food security for a rapidly growing world population, and a subsidiary of Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Adrian Percy to its board of directors. Dr. Percy, who also serves as a member of Evogene Ltd.'s board of directors since March 2019, brings a wealth of expertise and a deep commitment to advancing environmentally friendly agricultural technologies. With over 25 years of experience in the agricultural industry, Dr. Adrian Percy strongly advocates for environmentally friendly agricultural and f

      7/12/23 7:00:00 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials

    $EVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital reiterated coverage on EverGen Infrastructure with a new price target

      RBC Capital reiterated coverage of EverGen Infrastructure with a rating of Outperform and set a new price target of $7.00 from $8.00 previously

      11/24/21 7:31:39 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • ROTH Capital initiated coverage on Evogene with a new price target

      ROTH Capital initiated coverage of Evogene with a rating of Buy and set a new price target of $7.00

      10/8/21 8:30:09 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials
    • RBC Capital initiated coverage on EverGen Infrastructure Corp. with a new price target

      RBC Capital initiated coverage of EverGen Infrastructure Corp. with a rating of Outperform and set a new price target of $8.00

      8/23/21 11:09:14 AM ET
      $EVGN
      Agricultural Chemicals
      Industrials